{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:35:58Z","timestamp":1773275758395,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00262-008-0464-y","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T09:11:12Z","timestamp":1202893872000},"page":"1711-1717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The \u201cA, B and C\u201d of Her-2 DNA vaccine development"],"prefix":"10.1007","volume":"57","author":[{"given":"Wei-Zen","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Radkevich-Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Whittington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-chi M.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"issue":"12 Suppl 4","key":"464_CR1","first-page":"51","volume":"26","author":"MC Hung","year":"1999","unstructured":"Hung MC, Lau YK (1999) Basic science of HER-2\/neu: a review. Semin Oncol 26(12 Suppl 4):51\u201359","journal-title":"Semin Oncol"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712","journal-title":"Science"},{"key":"464_CR3","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/j.1460-2075.1994.tb06632.x","volume":"13","author":"R Ben-Levy","year":"1994","unstructured":"Ben-Levy R, Paterson HF, Marshall CJ et al (1994) A single autophosphorylation site confers oncogenicity tothe Neu\/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13:3302\u20133311","journal-title":"EMBO J"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/0092-8674(90)90697-D","volume":"61","author":"T Wada","year":"1990","unstructured":"Wada T, Qian XL, Greene MI (1990) Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339\u20131347","journal-title":"Cell"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6","volume":"81","author":"WZ Wei","year":"1999","unstructured":"Wei WZ, Shi WP, Galy A et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748\u2013754","journal-title":"Int J Cancer"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"464_CR7","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.167.6.3201","volume":"167","author":"SA Pilon","year":"2001","unstructured":"Pilon SA, Piechocki MP, Wei WZ (2001) Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167:3201\u20133206","journal-title":"J Immunol"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0065-230X(02)85004-7","volume":"85","author":"R Kiessling","year":"2002","unstructured":"Kiessling R, Wei WZ, Herrmann F et al (2002) Cellular immunity to the Her-2\/neu protooncogene. Adv Cancer Res 85:101\u2013144","journal-title":"Adv Cancer Res"},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0022-1759(01)00487-2","volume":"259","author":"MP Piechocki","year":"2002","unstructured":"Piechocki MP, Pilon SA, Wei WZ (2002) Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 259:33\u201342","journal-title":"J Immunol Methods"},{"key":"464_CR10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.4049\/jimmunol.170.3.1202","volume":"170","author":"SA Pilon","year":"2003","unstructured":"Pilon SA, Kelly C, Wei WZ (2003) Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170:1202\u20131208","journal-title":"J Immunol"},{"key":"464_CR11","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","volume":"171","author":"MP Piechocki","year":"2003","unstructured":"Piechocki MP, Ho YS, Pilon S et al (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171:5787\u20135794","journal-title":"J Immunol"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ijc.11654","volume":"109","author":"JA Lindencrona","year":"2004","unstructured":"Lindencrona JA, Preiss S, Kammertoens T et al (2004) CD4+ T cell-mediated HER-2\/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259\u2013264","journal-title":"Int J Cancer"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-003-0444-1","volume":"53","author":"WZ Wei","year":"2004","unstructured":"Wei WZ, Morris GP, Kong YM (2004) Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73\u201378","journal-title":"Cancer Immunol Immunother"},{"key":"464_CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/BD-2004-20106","volume":"20","author":"F Miller","year":"2004","unstructured":"Miller F, Jones RF, Jacob J et al (2004) From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis 20:43\u201351","journal-title":"Breast Dis"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1158\/0008-5472.CAN-05-0934","volume":"65","author":"WZ Wei","year":"2005","unstructured":"Wei WZ, Jacob JB, Zielinski JF et al (2005) Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 65:8471\u20138478","journal-title":"Cancer Res"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cellimm.2006.07.002","volume":"240","author":"J Jacob","year":"2006","unstructured":"Jacob J, Radkevich O, Forni G et al (2006) Activity of DNA vaccines encoding self or heterologous Her-2\/neu in Her-2 or neu transgenic mice. Cell Immunol 240:96\u2013106","journal-title":"Cell Immunol"},{"key":"464_CR17","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4049\/jimmunol.167.6.3367","volume":"167","author":"MP Piechocki","year":"2001","unstructured":"Piechocki MP, Pilon SA, Wei WZ (2001) Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367\u20133374","journal-title":"J Immunol"},{"key":"464_CR18","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1158\/0008-5472.CAN-06-4755","volume":"67","author":"JB Jacob","year":"2007","unstructured":"Jacob JB, Kong YM, Meroueh C et al (2007) Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res 67:7020\u20137027","journal-title":"Cancer Res"},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc2127","volume":"7","author":"J Ursini-Siegel","year":"2007","unstructured":"Ursini-Siegel J, Schade B, Cardiff RD et al (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7:389\u2013397","journal-title":"Nat Rev Cancer"},{"key":"464_CR20","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","volume":"165","author":"S Rovero","year":"2000","unstructured":"Rovero S, Amici A, Carlo ED et al (2000) DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice. J Immunol 165:5133\u20135142","journal-title":"J Immunol"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1158\/0008-5472.CAN-07-0765","volume":"67","author":"MP Piechocki","year":"2007","unstructured":"Piechocki MP, Yoo GH, Dibbley SK et al (2007) Breast cancer expressing the activated HER2\/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2\/neu. Cancer Res 67:6825\u20136843","journal-title":"Cancer Res"},{"key":"464_CR22","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211\u20135218","journal-title":"J Immunol"},{"key":"464_CR23","first-page":"3569","volume":"60","author":"RT Reilly","year":"2000","unstructured":"Reilly RT, Gottlieb MB, Ercolini AM et al (2000) HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice. Cancer Res 60:3569\u20133576","journal-title":"Cancer Res"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00262-006-0237-4","volume":"56","author":"R Singh","year":"2007","unstructured":"Singh R, Paterson Y (2007) In the FVB\/N HER-2\/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2\/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother 56:927\u2013938","journal-title":"Cancer Immunol Immunother"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.1158\/0008-5472.CAN-05-0666","volume":"65","author":"R Bos","year":"2005","unstructured":"Bos R, van DS, van HT et al (2005) Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 65:6443\u20136449","journal-title":"Cancer Res"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.20536","volume":"113","author":"P Gallo","year":"2005","unstructured":"Gallo P, Dharmapuri S, Nuzzo M et al (2005) Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113:67\u201377","journal-title":"Int J Cancer"},{"key":"464_CR27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/0008-5472.1071.65.3","volume":"65","author":"SM Pupa","year":"2005","unstructured":"Pupa SM, Iezzi M, Di CE et al (2005) Inhibition of mammary carcinoma development in HER-2\/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65:1071\u20131078","journal-title":"Cancer Res"},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1158\/0008-5472.CAN-05-0335","volume":"65","author":"K Tegerstedt","year":"2005","unstructured":"Tegerstedt K, Lindencrona JA, Curcio C et al (2005) A single vaccination with polyomavirus VP1\/VP2Her2 virus-like particles prevents outgrowth of HER-2\/neu-expressing tumors. Cancer Res 65:5953\u20135957","journal-title":"Cancer Res"},{"key":"464_CR29","first-page":"1175","volume":"79","author":"W Huang","year":"1999","unstructured":"Huang W, Kukes GD (1999) Hashimoto\u2019s thyroiditis: an organ-specific autoimmune disease-pathogenesis and recent developments. Lab Invest 79:1175\u20131180","journal-title":"Lab Invest"},{"key":"464_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/0090-1229(84)90115-6","volume":"32","author":"GW Canonica","year":"1984","unstructured":"Canonica GW, Cosulich ME, Croci R et al (1984) Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto\u2019s thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. Clin Immunol Immunopathol 32:132\u2013141","journal-title":"Clin Immunol Immunopathol"},{"key":"464_CR31","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1210\/jc.2002-020492","volume":"87","author":"B Vaidya","year":"2002","unstructured":"Vaidya B, Kendall-Taylor P, Pearce SHS (2002) Genetics of endocrine disease: the genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 87:5385\u20135397","journal-title":"J Clin Endocrinol Metab"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1084\/jem.184.3.1167","volume":"184","author":"YM Kong","year":"1996","unstructured":"Kong YM, Lomo LC, Motte RW et al (1996) HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 184:1167\u20131172","journal-title":"J Exp Med"},{"key":"464_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s002510050277","volume":"46","author":"YM Kong","year":"1997","unstructured":"Kong YM, David CS, Lomo LC et al (1997) Role of mouse and human class II transgenes in susceptibility to and protection against mouse autoimmune thyroiditis. Immunogenetics 46:312\u2013317","journal-title":"Immunogenetics"},{"key":"464_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.174.4014.1137","volume":"174","author":"AO Vladutiu","year":"1971","unstructured":"Vladutiu AO, Rose NR (1971) Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type. Science 174:1137\u20131139","journal-title":"Science"},{"key":"464_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.coi.2004.07.014","volume":"16","author":"CE Larsen","year":"2004","unstructured":"Larsen CE, Alper CA (2004) The genetics of HLA-associated disease. Curr Opin Immunol 16:660\u2013667","journal-title":"Curr Opin Immunol"},{"key":"464_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.humimm.2004.02.026","volume":"65","author":"L Levin","year":"2004","unstructured":"Levin L, Ban Y, Concepcion E et al (2004) Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Hum Immunol 65:640\u2013647","journal-title":"Hum Immunol"},{"key":"464_CR37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1084\/jem.145.5.1250","volume":"145","author":"PS Esquivel","year":"1977","unstructured":"Esquivel PS, Rose NR, Kong YM (1977) Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med 145:1250\u20131263","journal-title":"J Exp Med"},{"key":"464_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/eji.1830110216","volume":"11","author":"M Elrehewy","year":"1981","unstructured":"Elrehewy M, Kong YM, Giraldo AA et al (1981) Syngeneic thyroglobulin is immunogenic in good responder mice. Eur J Immunol 11:146\u2013151","journal-title":"Eur J Immunol"},{"key":"464_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1023\/A:1021904432489","volume":"23","author":"DG McNeel","year":"2003","unstructured":"McNeel DG, Knutson KL, Schiffman K et al (2003) Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 23:62\u201372","journal-title":"J Clin Immunol"},{"key":"464_CR40","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/blood.V99.8.2845","volume":"99","author":"ML Disis","year":"2002","unstructured":"Disis ML, Rinn K, Knutson KL et al (2002) Flt3 ligand as a vaccine adjuvant in association with HER-2\/neu peptide-based vaccines in patients with HER-2\/neu-overexpressing cancers. Blood 99:2845\u20132850","journal-title":"Blood"},{"key":"464_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev.immunol.18.1.423","volume":"18","author":"EM Shevach","year":"2000","unstructured":"Shevach EM (2000) Regulatory T cells in autoimmmunity. Annu Rev Immunol 18:423\u2013449","journal-title":"Annu Rev Immunol"},{"key":"464_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0090-1229(89)90204-3","volume":"51","author":"YM Kong","year":"1989","unstructured":"Kong YM, Giraldo AA, Waldmann H et al (1989) Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of boththyroglobulin-activated and TSH-induced suppression. Clin Immunol Immunopathol 51:38\u201354","journal-title":"Clin Immunol Immunopathol"},{"key":"464_CR43","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151\u20131164","journal-title":"J Immunol"},{"key":"464_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cellimm.2003.11.002","volume":"226","author":"GP Morris","year":"2003","unstructured":"Morris GP, Chen L, Kong YM (2003) CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 226:20\u201329","journal-title":"Cell Immunol"},{"key":"464_CR45","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.174.5.3111","volume":"174","author":"GP Morris","year":"2005","unstructured":"Morris GP, Yan Y, David CS et al (2005) H2A- and H2E-derived CD4+CD25+ regulatory T cells: a potential role in reciprocal inhibition by class II genes in autoimmune thyroiditis. J Immunol 174:3111\u20133116","journal-title":"J Immunol"},{"key":"464_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2005.09.003","volume":"26","author":"GP Morris","year":"2006","unstructured":"Morris GP, Kong YM (2006) Interference with CD4(+)CD25(+) T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody. J Autoimmun 26:24\u201331","journal-title":"J Autoimmun"},{"key":"464_CR47","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","volume":"175","author":"AV Maker","year":"2005","unstructured":"Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746\u20137754","journal-title":"J Immunol"},{"key":"464_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593\u2013598","journal-title":"J Immunother"},{"key":"464_CR49","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043\u20136053","journal-title":"J Clin Oncol"},{"key":"464_CR50","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","volume":"12","author":"AV Maker","year":"2005","unstructured":"Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study. Ann Surg Oncol 12:1005\u20131016","journal-title":"Ann Surg Oncol"},{"key":"464_CR51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","volume":"27","author":"MR Robinson","year":"2004","unstructured":"Robinson MR, Chan CC, Yang JC et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478\u2013789","journal-title":"J Immunother"},{"key":"464_CR52","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372\u20138377","journal-title":"Proc Natl Acad Sci USA"},{"key":"464_CR53","first-page":"63","volume-title":"Autoimmunity: genetics, immunologic, virologic, and clinical aspects","author":"NR Rose","year":"1977","unstructured":"Rose NR, Bacon LD, Sundick RS et al (1977) Genetic regulation in autoimmune thyroiditis. In: Talal N (ed) Autoimmunity: genetics, immunologic, virologic, and clinical aspects. Academic Press, New York, pp 63\u201387"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-008-0464-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0464-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-008-0464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:18:44Z","timestamp":1744165124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-008-0464-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,14]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s00262-008-0464-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,14]]},"assertion":[{"value":"12 December 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}